Ser361

Site Information
RFCDsPtsDLEMRNG SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 4755373

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 )
Disease tissue studied:	breast cancer ( 1 ) , cervical cancer ( 11 ) , cervical adenocarcinoma ( 11 ) , leukemia ( 5 , 13 ) , acute myelogenous leukemia ( 5 ) , chronic myelogenous leukemia ( 13 ) , lung cancer ( 3 , 10 ) , non-small cell lung cancer ( 3 )
Relevant cell line - cell type - tissue:	293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 9 ) , 293E (epithelial) ( 6 ) , BT-474 (breast cell) ( 1 ) , Calu 6 (pulmonary) ( 3 ) , H2009 (pulmonary) ( 3 ) , H2077 (pulmonary) ( 3 ) , H2887 (pulmonary) ( 3 ) , H322M (pulmonary) ( 3 ) , HCC1359 (pulmonary) ( 3 ) , HCC2279 (pulmonary) ( 3 ) , HCC366 (pulmonary) ( 3 ) , HCC4006 (pulmonary) ( 3 ) , HCC78 (pulmonary) ( 3 ) , HCC827 (pulmonary) ( 3 ) , HeLa S3 (cervical) ( 11 ) , HOP62 (pulmonary) ( 3 ) , Jurkat (T lymphocyte) ( 2 , 7 , 8 , 12 ) , K562 (erythroid) ( 13 ) , KG-1 (myeloid) ( 5 ) , LCLC-103H (pulmonary) ( 3 ) , LOU-NH91 (squamous) ( 3 ) , lung ( 10 ) , NCI-H1395 (pulmonary) ( 3 ) , NCI-H1568 (pulmonary) ( 3 ) , NCI-H1648 (pulmonary) ( 3 ) , NCI-H2030 (pulmonary) ( 3 ) , NCI-H2172 (pulmonary) ( 3 ) , NCI-H322 (pulmonary) ( 3 ) , NCI-H460 (pulmonary) ( 3 ) , NCI-H520 (squamous) ( 3 ) , NCI-H647 (pulmonary) ( 3 ) , PC9 (pulmonary) ( 3 )

Upstream Regulation
Treatments:	nocodazole ( 11 )

References
1	Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290 27362937 Curated Info
2	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
3	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
4	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
5	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
6	Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22 21659604 Curated Info
7	Guo A (2011) CST Curation Set: 11849; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTDXEAntibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) CK2 Substrate (P-S/T3-100) Rabbit mAb Cat#: 8738 Curated Info
8	Guo A (2011) CST Curation Set: 11850; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](D/E)X(D/E) Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) CKII Substrate Antibody (polyAb) Cat#: 5808, PTMScan(R) Phospho-CK Substrate Motif (S/TD/EXD/E) Immunoaffinity Beads Cat#: 1994 Curated Info
9	Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53 20363803 Curated Info
10	Rikova K (2010) CST Curation Set: 9770; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
11	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
12	Possemato A (2009) CST Curation Set: 6383; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XXp[ST] Curated Info
13	Stokes M (2008) CST Curation Set: 4388; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info